DoctorAdam vs Ro
Two GLP-1 desks, one scoreboard. We put DoctorAdam and Ro head-to-head on the published Brief Score — the same six factors, scored the same way.
The verdict
Ro takes this head-to-head.
Ro scores 87 to 75 on our six-factor Brief Score — A heavyweight platform with brand-name access and a polished experience — but it keeps compounded pricing off the record.
That doesn't make DoctorAdam a bad call — it's best for readers who want adults seeking compounded oral or injectable glp-1s with flat all-in monthly pricing. Weigh the six factors below against your own priorities before you decide.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| DoctorAdam | Ro | |
|---|---|---|
| Brief Score | 75/100 (C) | 87/100 (B+) |
| Semaglutide | From $129/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | From $229/mo (starting dose, compounded) | Not disclosed |
| Coverage | 44 states | Multi-state |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Newnew to the tracker, no prior reading | Stableprice stable |
DoctorAdam: New to the tracker on 1 August 2026. The published line reads From $129/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
● Not sold on either?
CoreAge Rx tops the whole ranking at 94/100.
The steadiest desk in the ranking: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.